News

Video

Tremelimumab Plus Durvalumab in Patients With Advanced HCC: The HIMALAYA Study

Dr R. Katie Kelley shares her thoughts on the four-year updated survival and efficacy data from the phase 3 HIMALAYA trial in patients with advanced hepatocellular carcinoma.

Related Videos
Related Content